序号 |
标题 |
次数 |
作者 |
发布时间 |
81181 |
MMA-DOTA-Cys 61 ,DOTA-马来酰亚胺-半胱氨酸 |
133 |
wyh |
2024-12-03 |
81182 |
DOTA-BR96 ,DOTA标记BR96单克隆抗体 |
106 |
wyh |
2024-12-03 |
81183 |
DOTA-ggNle-cycmsh(hex),内酰胺桥环化肽偶联DOTA |
92 |
wyh |
2024-12-03 |
81184 |
DOTA-sCCK8[Phe2(p-CH2SO3H) ,大环DOTA偶联多肽 |
96 |
wyh |
2024-12-03 |
81185 |
3,6-双(1H-1,2,3,4-四唑-5-基氨基)-1,2,4,5-四嗪(BTATz);3,6-bis(1H-1,2,3,4-tetrazol-5-yl-amino)- 1,2,4,5-tetrazine |
107 |
WYQ |
2024-12-03 |
81186 |
3,3'-偶氮二(6-氨基-1,2,4,5-四嗪)(DAAT);3,3'-azobis(6-amino-1,2,4,5-tetrazine) |
184 |
WYQ |
2024-12-03 |
81187 |
c(DOTA-RGDf),大环螯合剂DOTA环化RGD肽序列 |
102 |
wyh |
2024-12-03 |
81188 |
3,6-双(吡啶-3-基)-1,2,4,5-四嗪(3,3'-吡喃);3,6-bis(pyridin-3-yl)-1,2,4,5-tetrazine (3,3'-pytz) |
111 |
WYQ |
2024-12-03 |
81189 |
3,6-双(2-甲氧基苯基)-1,2-二氢-1,2,4,5-四嗪(2-MDHT);3,6-bis(2-methoxyphenyl)-1,2-dihydro-1,2,4,5-tetrazine |
121 |
WYQ |
2024-12-03 |
81190 |
3,6-二甲基-1,2,4,5-四嗪;3,6-Dimethyl-1,2,4,5-tetrazine |
124 |
WYQ |
2024-12-03 |
81191 |
3,3'-偶氮(6-氨基-1,2,4,5-四嗪);3,3'-Azobis(6-amino-1,2,4,5-tetrazine)(DAAT) |
152 |
WYQ |
2024-12-03 |
81192 |
3,6-d二肼基-1,2,4,5-四嗪(DHT) |
110 |
WYQ |
2024-12-03 |
81193 |
DOTA-D-phe1-Tyr3-奥曲肽 ,Ga-68-DOTA-TATE |
90 |
wyh |
2024-12-03 |
81194 |
DOTA-cCCK,DOTA偶联胆囊收缩素(CCK)受体 |
117 |
wyh |
2024-12-03 |
81195 |
3,6-d氨基-1,2,4,5-四嗪(DATZ) |
106 |
WYQ |
2024-12-03 |
81196 |
3-d氨基-6-(3,5-二甲基乙基吡唑-1-基)-1,2,4,5-四嗪(ADMPT) |
120 |
WYQ |
2024-12-03 |
81197 |
[DOTA]LTT-SS28 ,生长抑素模拟物 |
137 |
wyh |
2024-12-03 |
81198 |
DOTA-minigastrin (CP04) , DOTA-小胃泌素(CP04) |
141 |
wyh |
2024-12-03 |
81199 |
DOTA-rhuEpo ; DOTA-酰肼偶联rhuEpo |
85 |
wyh |
2024-12-03 |
81200 |
1,2,4,5-四嗪 , 化学式:C2H2N4 |
157 |
WYQ |
2024-12-03 |
81201 |
DOTA-Benerotide ;靶向生长抑素受体 |
75 |
wyh |
2024-12-03 |
81202 |
1,2,4,5-Tetrazines by Palladium Catalysis(钯催化1,2,4,5-四嗪的合成) |
88 |
WYQ |
2024-12-03 |
81203 |
5-苯基-1,2,4-三嗪-3-胺为例,为C9H8N4 |
89 |
WYQ |
2024-12-03 |
81204 |
DOTA-PEG-LA-AuNP,DOTA-PEG-硫辛酸修饰纳米金纳米粒子 |
109 |
wyh |
2024-12-03 |
81205 |
3,6-二(吡啶-2-基)-1,2,4,5-四嗪(pytz) |
136 |
WYQ |
2024-12-03 |
81206 |
HYNIC-PEG11-Tz;联肼尼克酰胺-十一聚乙二醇-四嗪;HYNIC-PEG11-Tetrazine |
92 |
WYQ |
2024-12-03 |
81207 |
DOTA-NT肽偶联金纳米粒子 ,DOTA-NT-AuNPs |
85 |
wyh |
2024-12-03 |
81208 |
[Zr-89]Zr-DFO-PEG5-Tz;[Zr-89]Zr-DFO-PEG5-Tetrazine |
95 |
WYQ |
2024-12-03 |
81209 |
MeTz-NOTA-RGD;甲基四嗪-大环配体-多肽 |
128 |
WYQ |
2024-12-03 |
81210 |
DOTA-Tyr(3)-奥曲肽, DOTA-Tyr(3)-Octreotide |
72 |
wyh |
2024-12-03 |
81211 |
AgNPs–pytz(3,6-二(吡啶-2-基)-1,2,4,5-四嗪包覆的银纳米粒子) |
92 |
WYQ |
2024-12-03 |
81212 |
3,6-di(pyridin-2-yl)-1,2,4,5-s-tetrazine (pytz,3,6-二(吡啶-2-基)-1,4-二氢-1,2,4,5-四嗪) |
119 |
WYQ |
2024-12-03 |
81213 |
DOTA-叶酸偶联物,DOTA-Folate |
122 |
wyh |
2024-12-03 |
81214 |
CQDs-DOTA-Yb,镱-DOTA螯合物功能化碳量子点 |
103 |
wyh |
2024-12-03 |
81215 |
3,6-dihydrazino-s-tetrazine (DHT,3,6-二肼基-s-四嗪) |
115 |
WYQ |
2024-12-03 |
81216 |
BCN-PEG-PAMAM ,环丙烷环辛炔-聚乙二醇-聚酰胺 |
97 |
zyl |
2024-12-03 |
81217 |
(DNAZTzDMP)2Ni(H2O)2][NO3]2;3-(3,3'-二硝基氮杂环丁烷)-6-(3,5-二甲基吡唑)四嗪配合物 |
100 |
WYQ |
2024-12-03 |
81218 |
AB1-HLys-DOTA,DOTA偶联阳离子肽 |
89 |
wyh |
2024-12-03 |
81219 |
PAMAM-PEG-CKAAKN 树枝状大分子聚酰胺胺-聚乙二醇-CKAAKN多肽 |
97 |
zyl |
2024-12-03 |
81220 |
(NH2TzDMP)3Ni][NO3]2;3-氨基-6-(3,5-二甲基吡唑)四嗪配合物 |
78 |
WYQ |
2024-12-03 |
81221 |
(DNAZTzDMP)2Co(H2O)2;3-(3,3'-二硝基氮杂环丁烷)-6-(3,5-二甲基吡唑)四嗪配合物 |
115 |
WYQ |
2024-12-03 |
81222 |
DOTA-1-nal 3-奥曲肽,Ga-DOTA-1-Nal3-octreotide |
70 |
wyh |
2024-12-03 |
81223 |
PAMAM-PEG-SP94 树枝状大分子聚酰胺胺-聚乙二醇-SP94多肽 |
98 |
zyl |
2024-12-03 |
81224 |
[(DNAZTzDMP)2Co(H2O)2](3-(3,3'-二硝基氮杂环丁烷)-6-(3,5-二甲基吡唑)四嗪配合物) |
125 |
WYQ |
2024-12-03 |
81225 |
LLP2A-DOTA-PEG(2000), LLP2A-DOTA-聚乙二醇(2000) |
84 |
wyh |
2024-12-03 |